Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Biomarker Modulation by Inhibition of EGFR and/or Src Family Kinases Using Erlotinib and Dasatinib in Head and Neck Lung Cancers

NCT00779389 is registered in ClinicalTrials.gov with University of Pittsburgh as lead sponsor.

NCT NCT00779389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00779389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Biomarker Modulation by Inhibition of EGFR and/or Src Family Kinases Using Erlotinib and Dasatinib in Head and Neck Lung Cancers
Lead sponsor
University of Pittsburgh
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2009
Completion date
February 28, 2014
Enrollment
58 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, non small cell lung cancer